---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-051551"
form_type: "8-K"
ticker: "ZBH"
cik: "0001136869"
company_name: "ZIMMER BIOMET HOLDINGS, INC."
filed_at: "2024-05-02T23:59:59+00:00"
generated_at: "2026-06-02T23:55:40.004244+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Zimmer Biomet Q1 net sales $1.889B (+3.2%); adj. EPS $1.94; reiterates FY guidance

## Summary
- Net sales $1.889B, up 3.2% reported and 4.4% constant currency; GAAP diluted EPS $0.84, adjusted $1.94.
- Knees $788.1M (+3.4%), Hips $491.2M (-0.3%), S.E.T. $452.6M (+4.4%).
- Reiterates FY2024 guidance: constant currency revenue growth 5-6%, adjusted EBITDA $8.00-$8.15 EPS.
- FDA 510(k) clearance for ROSA Shoulder System (first robotic shoulder assist) and Z1 Femoral Hip Stem.

## SEC filing metadata
- accession: 0000950170-24-051551
- form_type: 8-K
- ticker: ZBH
- cik: 0001136869
- company_name: ZIMMER BIOMET HOLDINGS, INC.
- filed_at: 2024-05-02T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/zbh-20240502.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-051551
- JSON: https://secwatch.observer/filing/0000950170-24-051551.json
- Plain text: https://secwatch.observer/filing/0000950170-24-051551.txt

## Key facts
- Earnings Releases
  ZIMMER BIOMET HOLDINGS, INC. updated its full-year 2024 guidance (reaffirmed).
  - Period: full-year 2024
  - Guidance: reaffirmed
  - Result: guidance update
  source text: The Company is reiterating its current full-year 2024 financial guidance. Projected Year Ending December 31, 2024 2024 Reported Revenue Change 4.5% - 5.5% Foreign Currency Exchange Impact (0.5)% 2024 Constant Currency Revenue Change 5.0% - 6.0% Adjusted Diluted EPS (1) $8.00 - $8.15
  evidence_url: https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm
- Earnings Releases
  ZIMMER BIOMET HOLDINGS, INC. reported quarter ended March 31, 2024 results: revenue $1.889 billion, net income $172.4 million, EPS $0.84.
  - Period: quarter ended March 31, 2024
  - Revenue: $1.889 billion
  - Net income: $172.4 million
  - EPS: $0.84
  - Result: reported results
  source text: The Company reported first quarter net sales of $1.889 billion, an increase of 3.2% over the prior year period, and an increase of 4.4% on a constant currency 1 basis. Net earnings for the first quarter were $172.4 million, or $399.7 million on an adjusted 1 basis. Diluted earnings per share were $0.84 for the first quarter, and adjusted 1 diluted earnings per share were $1.94.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1136869/000095017024051551/0000950170-24-051551-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.